Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01553916 · ClinicalTrials.gov registry record · Phase 1
Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01553916 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 19 participants.
The verdict
NCT01553916, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation). PCI is used to prevent cancer metastases from returning in the brain. This treatment can cause short-term memory problems by damaging the hippocampus. Lithium may help prevent or lessen memory problems caused by PCI by protecting the hippocampus.
Interventions
- DRUG Lithium Carbonate
- RADIATION Prophylactic cranial irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-04-26 |
| Est. Completion | 2017-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01553916
The ClinicalTrials.gov registry entry for NCT01553916 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lithium Carbonate is the first listed.
NCT01553916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01553916 about?
NCT01553916 is a clinical study titled "Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain". This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation). PCI is used to prevent cancer metastases from returning in the brain. This trea...
What is the current status of trial NCT01553916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-04-26. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT01553916?
The interventions under investigation include: Lithium Carbonate (DRUG), Prophylactic cranial irradiation (RADIATION).
Who is sponsoring clinical trial NCT01553916?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.